BioNTech agrees to acquire former COVID vaccine rival CureVac
12/06/2025 11:51
June 12 (Reuters) - German biotech firm BioNTech 22UAy.DE said on Thursday it agreed to acquire domestic peer CureVac 5CV.DE for about $1.25 billion worth of BioNTech shares, eyeing a combination of the two former rivals in the race to develop COVID-19 vaccines. (Reporting by Ludwig Burger, Editing by Friederike Heine) ((ludwig.burger@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028